Leonteq Securities AG Invests $650,000 in Elevance Health, Inc. $ELV

Leonteq Securities AG bought a new position in shares of Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,854 shares of the company’s stock, valued at approximately $650,000.

A number of other institutional investors also recently modified their holdings of ELV. Artisan Partners Limited Partnership boosted its holdings in shares of Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC boosted its holdings in shares of Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after purchasing an additional 798,457 shares during the period. Brave Warrior Advisors LLC boosted its holdings in shares of Elevance Health by 65.3% during the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after purchasing an additional 724,349 shares during the period. Baupost Group LLC MA boosted its holdings in shares of Elevance Health by 114.1% during the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock worth $426,195,000 after purchasing an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of Elevance Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after purchasing an additional 627,038 shares during the period. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELV has been the subject of several research analyst reports. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective for the company. in a report on Tuesday, February 3rd. JPMorgan Chase & Co. raised their price objective on shares of Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Bank of America upgraded shares of Elevance Health from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $405.00 to $435.00 in a report on Wednesday, April 29th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and lifted their target price for the company from $363.00 to $498.00 in a report on Wednesday. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $399.32.

Elevance Health Price Performance

Shares of ELV opened at $394.41 on Friday. The company has a market capitalization of $85.65 billion, a P/E ratio of 16.78, a price-to-earnings-growth ratio of 2.21 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $333.81 and a 200 day moving average of $336.25. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $408.00.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the firm earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities research analysts anticipate that Elevance Health, Inc. will post 26.91 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.